The impact of the AIDS drug assistance program (ADAP) on use of highly active antiretroviral and antihypertensive therapy among HIV-infected women

Thomas Yi, Jennifer Cocohoba, Mardge Cohen, Kathryn Anastos, Jack A. Dehovitz, Naoko Kono, David B. Hanna, Nancy A. Hessol

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives: To evaluate the association between enrollment into an AIDS Drug Assistance Program (ADAP) and use of highly active antiretroviral therapy (HAART) and antihypertensive therapy. Methods: Cross-sectional analyses of data were performed on HAART-eligible women enrolled in the California (n = 439), Illinois (n = 168), and New York (n = 487) Women's Interagency HIV Study sites. A subset of HIV-infected women with hypertension (n = 395) was also analyzed. Unadjusted and adjusted backward stepwise elimination logistic regression measured the association between demographic, behavioral, and health service factors and nonuse of HAART or antihypertensive medication. Results: In adjusted analysis of HAART nonuse, women without ADAP were significantly more likely not to use HAART (odds ratio [OR], 2.4; 95% confidence interval [CI], 1.5-3.7) than women with ADAP. In adjusted analysis of antihypertensive medication nonuse, women without ADAP had an increased but not significant odds of antihypertensive medication nonuse (OR, 2.4; 95% CI, 0.93-6.0) than women with ADAP. Conclusions: Government-funded programs for prescription drug coverage such as ADAP may play an important role in how HIV-positive women access and use essential medications for chronic diseases.

Original languageEnglish (US)
Pages (from-to)253-262
Number of pages10
JournalJournal of Acquired Immune Deficiency Syndromes
Volume56
Issue number3
DOIs
StatePublished - Mar 1 2011

Fingerprint

Anti-HIV Agents
Highly Active Antiretroviral Therapy
Antihypertensive Agents
HIV
Odds Ratio
Government Programs
Confidence Intervals
Prescription Drugs
Health Services
Chronic Disease
Cross-Sectional Studies
Logistic Models
Demography
Hypertension

Keywords

  • AIDS
  • antiretroviral therapy
  • healthcare disparity
  • hypertension
  • prescription insurance
  • women

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

The impact of the AIDS drug assistance program (ADAP) on use of highly active antiretroviral and antihypertensive therapy among HIV-infected women. / Yi, Thomas; Cocohoba, Jennifer; Cohen, Mardge; Anastos, Kathryn; Dehovitz, Jack A.; Kono, Naoko; Hanna, David B.; Hessol, Nancy A.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 56, No. 3, 01.03.2011, p. 253-262.

Research output: Contribution to journalArticle

@article{99ba52d07cff464588632700d39f901e,
title = "The impact of the AIDS drug assistance program (ADAP) on use of highly active antiretroviral and antihypertensive therapy among HIV-infected women",
abstract = "Objectives: To evaluate the association between enrollment into an AIDS Drug Assistance Program (ADAP) and use of highly active antiretroviral therapy (HAART) and antihypertensive therapy. Methods: Cross-sectional analyses of data were performed on HAART-eligible women enrolled in the California (n = 439), Illinois (n = 168), and New York (n = 487) Women's Interagency HIV Study sites. A subset of HIV-infected women with hypertension (n = 395) was also analyzed. Unadjusted and adjusted backward stepwise elimination logistic regression measured the association between demographic, behavioral, and health service factors and nonuse of HAART or antihypertensive medication. Results: In adjusted analysis of HAART nonuse, women without ADAP were significantly more likely not to use HAART (odds ratio [OR], 2.4; 95{\%} confidence interval [CI], 1.5-3.7) than women with ADAP. In adjusted analysis of antihypertensive medication nonuse, women without ADAP had an increased but not significant odds of antihypertensive medication nonuse (OR, 2.4; 95{\%} CI, 0.93-6.0) than women with ADAP. Conclusions: Government-funded programs for prescription drug coverage such as ADAP may play an important role in how HIV-positive women access and use essential medications for chronic diseases.",
keywords = "AIDS, antiretroviral therapy, healthcare disparity, hypertension, prescription insurance, women",
author = "Thomas Yi and Jennifer Cocohoba and Mardge Cohen and Kathryn Anastos and Dehovitz, {Jack A.} and Naoko Kono and Hanna, {David B.} and Hessol, {Nancy A.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1097/QAI.0b013e31820a9d04",
language = "English (US)",
volume = "56",
pages = "253--262",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The impact of the AIDS drug assistance program (ADAP) on use of highly active antiretroviral and antihypertensive therapy among HIV-infected women

AU - Yi, Thomas

AU - Cocohoba, Jennifer

AU - Cohen, Mardge

AU - Anastos, Kathryn

AU - Dehovitz, Jack A.

AU - Kono, Naoko

AU - Hanna, David B.

AU - Hessol, Nancy A.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Objectives: To evaluate the association between enrollment into an AIDS Drug Assistance Program (ADAP) and use of highly active antiretroviral therapy (HAART) and antihypertensive therapy. Methods: Cross-sectional analyses of data were performed on HAART-eligible women enrolled in the California (n = 439), Illinois (n = 168), and New York (n = 487) Women's Interagency HIV Study sites. A subset of HIV-infected women with hypertension (n = 395) was also analyzed. Unadjusted and adjusted backward stepwise elimination logistic regression measured the association between demographic, behavioral, and health service factors and nonuse of HAART or antihypertensive medication. Results: In adjusted analysis of HAART nonuse, women without ADAP were significantly more likely not to use HAART (odds ratio [OR], 2.4; 95% confidence interval [CI], 1.5-3.7) than women with ADAP. In adjusted analysis of antihypertensive medication nonuse, women without ADAP had an increased but not significant odds of antihypertensive medication nonuse (OR, 2.4; 95% CI, 0.93-6.0) than women with ADAP. Conclusions: Government-funded programs for prescription drug coverage such as ADAP may play an important role in how HIV-positive women access and use essential medications for chronic diseases.

AB - Objectives: To evaluate the association between enrollment into an AIDS Drug Assistance Program (ADAP) and use of highly active antiretroviral therapy (HAART) and antihypertensive therapy. Methods: Cross-sectional analyses of data were performed on HAART-eligible women enrolled in the California (n = 439), Illinois (n = 168), and New York (n = 487) Women's Interagency HIV Study sites. A subset of HIV-infected women with hypertension (n = 395) was also analyzed. Unadjusted and adjusted backward stepwise elimination logistic regression measured the association between demographic, behavioral, and health service factors and nonuse of HAART or antihypertensive medication. Results: In adjusted analysis of HAART nonuse, women without ADAP were significantly more likely not to use HAART (odds ratio [OR], 2.4; 95% confidence interval [CI], 1.5-3.7) than women with ADAP. In adjusted analysis of antihypertensive medication nonuse, women without ADAP had an increased but not significant odds of antihypertensive medication nonuse (OR, 2.4; 95% CI, 0.93-6.0) than women with ADAP. Conclusions: Government-funded programs for prescription drug coverage such as ADAP may play an important role in how HIV-positive women access and use essential medications for chronic diseases.

KW - AIDS

KW - antiretroviral therapy

KW - healthcare disparity

KW - hypertension

KW - prescription insurance

KW - women

UR - http://www.scopus.com/inward/record.url?scp=79951811535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951811535&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e31820a9d04

DO - 10.1097/QAI.0b013e31820a9d04

M3 - Article

C2 - 21239994

AN - SCOPUS:79951811535

VL - 56

SP - 253

EP - 262

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 3

ER -